Article:
Conaghan, PG orcid.org/0000-0002-3478-5665, Bowes, MA, Kingsbury, SR orcid.org/0000-0002-9917-1269 et al. (9 more authors) (2020) Disease-Modifying Effects of a Novel Cathepsin K Inhibitor in Osteoarthritis: A Randomized Controlled Trial. Annals of Internal Medicine, 172 (2). pp. 86-95. ISSN 0003-4819

https://doi.org/10.7326/M19-0675

Table 1. Baseline demographics (modified intent-to-treat population).

	Placebo (n=77)	MIV-711 100 mg (n=82)	MIV-711 200 mg (n=81)
Female, n (%)	62 (80.5)	64 (78.0)	58 (71.6)
Age, years, mean (SD)	62.3 (6.6)	61.2 (6.6)	62.0 (7.3)
Weight, kg, mean (SD)	87.1 (16.8)	86.0 (14.2)	86.6 (14.7)
BMI, kg/m^2, mean (SD)	32.5 (5.8)	32.0 (5.5)	32.0 (5.5)
Local K-L score 2/3	77	82	81
Independent K-L score, n (%)			
0	1 (1.3)	0	0
1	14 (18.2)	17 (20.7)	23 (28.4)
2	33 (42.9)	38 (46.3)	28 (34.6)
3	28 (36.4)	27 (32.9)	29 (35.8)
4	1 (1.3)	0	0
Missing	0	0	1 (1.2)
Duration of knee pain in the last 12 months, n (%)			
8–30 days	1 (1.3)	0	0
31–92 days	19 (24.7)	18 (22.0)	15 (18.5)
More than 92 days	57 (74.0)	64 (78.0)	66 (81.5)
Prior medications			
Analgesics	0	0	1 (1.2)
Other analgesics and antipyretics	5 (6.5)	8 (9.8)	4 (4.9)

BMI, body mass index; K-L, Kellgren-Lawrence; SD, standard deviation.

Table 2. Estimated mean (LS mean; 95% CI) change from baseline (week 0) to week 26 in primary and secondary efficacy outcomes (modified intent-to-treat population).

	Change from baseline (week 0) to week 26 *, LS mean (95% CI)							
	Placebo (n=77)		MIV-711 100 mg (n=82)			MIV-711 200 mg (n=81)		
	n		n		Difference (vs placebo)	n		Difference (vs placebo)
Primary outcome								
NRS overall pain severity score	69	-1.4 (-1.9, -0.8)	74	-1.7 (-2.3, -1.2)	-0.3 (-1.0, 0.3) (p=0.146)	72	-1.5 (-2.0, -0.9)	-0.1 (-0.7, 0.6) (p=0.41)
Secondary outcomes								
MRI of bone area (mm^2)	66	23.3 (15.7, 30.9)	69	7.9 (0.5, 15.3)	-15.4 (-26.0, -4.8) (p=0.002)	69	8.6 (1.1, 16.1)	-14.7 (-25.3, -4.0) (p=0.004)
MRI of cartilage thickness (mm)								
Femur region	66	-0.066 (-0.119, -0.013)	69	0.011 (-0.042, 0.063)	0.076 (0.002, 0.150) (p=0.023)	69	-0.022 (-0.074, 0.031)	0.044 (-0.031, 0.118) (p=0.125)
Tibia region	66	0.017 (-0.061, 0.095)	69	-0.024 (-0.099, 0.052)	-0.041 (-0.125, 0.044) (p=0.83)	69	-0.005 (-0.080, 0.071)	-0.022 (-0.107, 0.063) (p=0.69)
MRI of total bone marrow lesion volume (µL)	66	-811 (-1900, 282)	69	-1160 (-2230, -84.4)	-347 (-1880, 1190) (p=0.33)	69	-1050 (-2130, 34.8)	-234 (-1770, 1300) (p=0.38)
E-diary NRS scores								
AM response	69	-1.0 (-1.4, -0.6)	72	-1.4 (-1.8, -0.9)	-0.4 (-1.0, 0.2)	71	-1.4 (-1.9, -1.0)	-0.5 (-1.1, 0.2)
PM response	67	-1.2 (-1.6, -0.7)	67	-1.5 (-2.0, -1.1)	-0.3 (-1.0, 0.3)	70	-1.5 (-2.0, -1.1)	-0.4 (-1.0, 0.3)
Overall response	69	-1.1 (-1.6, -0.6)	72	-1.4 (-1.9, -1.0)	-0.3 (-1.0, 0.3)	71	-1.5 (-1.9, -1.0)	-0.4 (-1.0, 0.3)
Normalized WOMAC scores								
Pain score	69	-11.3 (-16.9, -5.7)	74	-15.9 (-21.3, -10.5)	-4.6 (-10.8, 1.7) (p=0.075)	72	-13.1 (-18.6, -7.6)	-1.8 (-8.0, 4.5) (p=0.29)

Function score	69	-11.9 (-18.1, -5.7)	74	-15.7 (-21.8, -9.6)	-3.8 (-10.3, 2.7) (p=0.126)	72	-13.8 (-19.9, -7.7)	-1.8 (-8.4, 4.7) (p=0.29)
Stiffness score	69	-11.0 (-17.8, -4.2)	74	-15.9 (-22.6, -9.3)	-5.0 (-12.1, 2.2) (p=0.086)	72	-14.1 (-20.8, -7.4)	-3.1 (-10.2, 4.1) (p=0.20)
Biomarkers								
Serum CTX-I (µg/L)	69	0.003 (-0.031, 0.037)	74	-0.143 (-0.175, -0.110)	-0.145 (-0.193, -0.098) (p<0.0001)	71	-0.251 (-0.285, -0.218)	-0.254 (-0.302, -0.206) (p<0.0001)
Urine CTX-II/Creat(ng/mmol)	68	41.9 (-23.0, 107)	73	-151 (-215, -87.6)	-193 (-262, -124) (p<0.0001)	72	-228 (-292, -165)	-270 (-339, -201) (p<0.0001)

CI, confidence interval; LS, least-squares; MRI, magnetic resonance imaging; NRS, numeric rating scale; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.

* Change from baseline was analyzed using a linear mixed model with baseline score as covariate and fixed factors for treatment, time, interaction for treatment-by-time, baseline analgesic user, and random effect for clinical site.

Table 3. Adverse events reported (SAF population).

	Placebo (n=80)	**MIV-711 100 mg (n=82)**	**MIV-711 200 mg (n=82)**
Any AE, n (%)	44 (55.0)	45 (54.9)	43 (52.4)
AEs occurring in ≥2% of participants overall, n (%)			
Nasopharyngitis	6 (7.5)	8 (9.8)	7 (8.5)
Osteoarthritis	7 (8.8)	7 (8.5)	6 (7.3)
Headache	6 (7.5)	5 (6.1)	5 (6.1)
Back pain	3 (3.8)	1 (1.2)	6 (7.3)
Diarrhea	3 (3.8)	4 (4.9)	2 (2.4)
Arthralgia	2 (2.5)	5 (6.1)	2 (2.4)
Nausea	2 (2.5)	1 (1.2)	4 (4.9)
Muscle spasms	1 (1.3)	6 (7.3)	0
Paraesthesia	3 (3.8)	1 (1.2)	3 (3.7)
Hypertension	4 (5.0)	0	1 (1.2)
Gamma-glutamyltransferase increased	4 (5.0)	1 (1.2)	0
Myalgia	1 (1.3)	2 (2.4)	2 (2.4)
Any SAE, n (%)	1 (1.3)	3 (3.7)	2 (2.4)
Atrial fibrillation	0	1 (1.2)	0
Cardiac failure	1 (1.3)	0	0
Prinzmetal angina	0	1 (1.2)	0
Cholecystitis acute	0	0	1 (1.2)
Pyelonephritis chronic	0	1 (1.2)	0
Compression fracture	0	1 (1.2)	0
Contusion	0	1 (1.2)	0
Cerebral infarction	0	0	1 (1.2)
Hematoma	0	1 (1.2)	0

(S)AE, (serious) adverse event; SAF, safety analysis population.